ridm@nrct.go.th   ระบบคลังข้อมูลงานวิจัยไทย   รายการโปรดที่คุณเลือกไว้

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

หน่วยงาน Nanyang Technological University, Singapore

รายละเอียด

ชื่อเรื่อง : ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
นักวิจัย : Souers, Andrew J. , Leverson, Joel D. , Boghaert, Erwin R. , Ackler, Scott L. , Catron, Nathaniel D. , Chen, Jun , Dayton, Brian D. , Ding, Hong , Enschede, Sari H. , Fairbrother, Wayne J. , Huang, David C. S. , Hymowitz, Sarah G. , Jin, Sha , Khaw, Seong Lin , Kovar, Peter J. , Lam, Lloyd T. , Lee, Jackie , Maecker, Heather L. , Marsh, Kennan C. , Mason, Kylie D. , Mitten, Michael J. , Nimmer, Paul M. , Oleksijew, Anatol , Park, Chang H. , Park, Cheol-Min , Phillips, Darren C. , Roberts, Andrew W. , Sampath, Deepak , Seymour, John F. , Smith, Morey L. , Sullivan, Gerard M. , Tahir, Stephen K. , Tse, Chris , Wendt, Michael D. , Xiao, Yu , Xue, John C. , Zhang, Haichao , Humerickhouse, Rod A. , Rosenberg, Saul H. , Elmore, Steven W.
คำค้น : DRNTU::Science::Chemistry::Biochemistry
หน่วยงาน : Nanyang Technological University, Singapore
ผู้ร่วมงาน : -
ปีพิมพ์ : 2556
อ้างอิง : Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., et al. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature medicine, 19(2), 202-208. , http://hdl.handle.net/10220/18024 , http://dx.doi.org/10.1038/nm.3048
ที่มา : -
ความเชี่ยวชาญ : -
ความสัมพันธ์ : Nature medicine
ขอบเขตของเนื้อหา : -
บทคัดย่อ/คำอธิบาย :

Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2–like 1 (BCL-XL), which has shown clinical efficacy in some BCL-2–dependent hematological cancers. However, concomitant on-target thrombocytopenia caused by BCL-XL inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199. This compound inhibits the growth of BCL-2–dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2–dependent hematological cancers.

บรรณานุกรม :